University of Texas: CAR T Cell Therapy Effective as First-Line Treatment for High-Risk Large B-Cell Lymphoma
December 07, 2020
December 07, 2020
HOUSTON, Texas, Dec. 7 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Dec. 6:
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.
Th . . .
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.
Th . . .